Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2020 1
2021 6
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent chronic lymphocytic leukemia: a case series and literature review.
Dirven I, Vander Mijnsbrugge AS, Mignon S, Tijtgat J, Kint N, Neyns B. Dirven I, et al. Among authors: tijtgat j. Melanoma Res. 2023 Aug 1;33(4):338-344. doi: 10.1097/CMR.0000000000000895. Epub 2023 Apr 28. Melanoma Res. 2023. PMID: 37114670 Review.
Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial.
Schwarze JK, Tijtgat J, Awada G, Cras L, Vasaturo A, Bagnall C, Forsyth R, Dufait I, Tuyaerts S, Van Riet I, Neyns B. Schwarze JK, et al. Among authors: tijtgat j. J Immunother Cancer. 2022 Sep;10(9):e005141. doi: 10.1136/jitc-2022-005141. J Immunother Cancer. 2022. PMID: 36113895 Free PMC article. Clinical Trial.
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial.
Duerinck J, Schwarze JK, Awada G, Tijtgat J, Vaeyens F, Bertels C, Geens W, Klein S, Seynaeve L, Cras L, D'Haene N, Michotte A, Caljon B, Salmon I, Bruneau M, Kockx M, Van Dooren S, Vanbinst AM, Everaert H, Forsyth R, Neyns B. Duerinck J, et al. Among authors: tijtgat j. J Immunother Cancer. 2021 Jun;9(6):e002296. doi: 10.1136/jitc-2020-002296. J Immunother Cancer. 2021. PMID: 34168003 Free PMC article. Clinical Trial.
Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma.
Tijtgat J, Geeraerts X, Boisson A, Stevens L, Vounckx M, Dirven I, Schwarze JK, Raeymaeckers S, Forsyth R, Van Riet I, Tuyaerts S, Willard-Gallo K, Neyns B. Tijtgat J, et al. J Immunother Cancer. 2024 Jan 11;12(1):e008148. doi: 10.1136/jitc-2023-008148. J Immunother Cancer. 2024. PMID: 38212127 Free PMC article.
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.
Awada G, Schwarze JK, Tijtgat J, Fasolino G, Kruse V, Neyns B. Awada G, et al. Among authors: tijtgat j. Melanoma Res. 2022 Jun 1;32(3):183-191. doi: 10.1097/CMR.0000000000000821. Epub 2022 Mar 29. Melanoma Res. 2022. PMID: 35377866 Clinical Trial.
Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial.
Schwarze JK, Garaud S, Jansen YJL, Awada G, Vandersleyen V, Tijtgat J, de Wind A, Kristanto P, Seremet T, Willard-Gallo K, Neyns B. Schwarze JK, et al. Among authors: tijtgat j. Cancers (Basel). 2022 Jan 28;14(3):682. doi: 10.3390/cancers14030682. Cancers (Basel). 2022. PMID: 35158952 Free PMC article.
14 results